ライフサイエンスコーパス: fusion protein

1 ed crystal structure of parainfluenzavirus 5 fusion protein.

2 etween the integrase and RDF moieties of the fusion protein.

3 e well-characterized nucleophosmin (NPM)-ALK fusion protein.

4 re metastases, than cells not expressing the fusion protein.

5 when expressed as isolated fragments or as a fusion protein.

6 ction prevented secretion of the Loop1-Loop7 fusion protein.

7 parental proteins are combined into a single fusion protein.

8 in a approximately 35 bp wide region by the fusion protein.

9 cell permeability and kinase activity of the fusion protein.

10 ne AML model driven by the MLL-AF9 oncogenic fusion protein.

11 glutide, a glucagon-like peptide 1 (GLP1)-Fc fusion protein.

12 d therapies are used to inhibit the ALK-EML4 fusion protein.

13 egulated when co-expressed with the J-domain fusion protein.

14 with different bispecific streptavidin-scFv fusion proteins.

15 spanins, which are similar to class I viral fusion proteins.

16 against other enveloped viruses with class I fusion proteins.

17 were not altered, despite a lower content of fusion proteins.

18 man and humanized IgG1 mAbs as well as of Fc-fusion proteins.

19 nels, which were expressed as GFP- or cherry-fusion proteins.

20 forms of leukemia and can lead to oncogenic fusion proteins.

21 t reveal homology to class II viral membrane fusion proteins.

22 ex1 proteins produced by in situ cleavage of fusion proteins.

23 CDK inhibitors in AML patients harboring MLL fusion proteins.

24 chromosomal translocations that create novel fusion proteins.

25 es them from many other low-pH-induced viral fusion proteins.

26 mains presented as human serum albumin (HSA) fusion proteins.

27 usly identifying catabolites for recombinant fusion proteins.

28 We detected MAN2A1-FER messenger RNA and fusion protein (114 kD) in the hepatocellular carcinoma

29 sses of EPIs that interact with the membrane fusion protein AcrA, a critical component of the AcrAB-T

30 This fusion protein allowed the induction of allergen-specifi

31 ng anti-SIRPalpha antibodies or SIRPalpha-Fc fusion protein also increased phagocytosis of P. falcipa

32 ay represent a widespread mechanism by which fusion proteins alter the topology of cellular signaling

33 The resultant in-frame fusion protein AML1-ETO (AE) acts as an initiating oncog

34 These features make the fusion protein an innovative step toward the development

35 abilized elastin-like polypeptide (ELP)-VEGF fusion protein and determined its in vivo potential for

36 identify myomerger as a fundamental myoblast fusion protein and establish a system that begins to rec

37 nding of p12-green fluorescent protein (GFP) fusion protein and functional complementation of p12-PM1

38 rs can be altered by inducing the OsMADS1-GR fusion protein and present a model for a regulatory casc

39 The fusion protein and recombinant human SDF1 showed similar

40 STM1 part determines the localization of the fusion protein and therefore the extent of the effect.

41 related carrier in the form of a recombinant fusion protein and used for sensitization.

42 r complex that makes direct contact with MLL fusion proteins and is involved in AML, however, its fun

43 To investigate the interplay of fusion proteins and microenvironment in lineage choice,

44 d to the heptad repeat B (HRB) region of the fusion protein, and no changes were observed in the vira

45 Both an HmpF-GFPuv fusion protein, and PilA, as assessed by in situ immunof

46 ngle CSP-hepatitis B surface antigen (HBsAg) fusion protein, and this leads to a vaccine composed of

47 ltivalent antibodies, bispecific antibodies, fusion proteins, and targeted nanoparticles that have be

48 Analysis using RNAi and HaloTag fusion protein approaches reveals that most TZPs (includ

49 fragment crystallizable (Fc) regions and Fc-fusion proteins are actively being explored as biomimeti

50 Here, we demonstrate that these fusion proteins are cleaved by caspases-1 and -11 at Asp

51 However, the signaling properties of fusion proteins are not consistent across GPCRs.

52 XTEN polymers and XTEN fusion proteins are typically expressed in Escherichia c

53 re significant, as they highlight the IL4-10 fusion protein as a long-needed potential new drug to st

54 e used a functional fluorescently tagged Rev fusion protein as a platform to study the effects of mod

55 tantly, the green fluorescent protein-SlGGB1 fusion protein as well as the carboxyl-terminal yellow f

56 Validation of FGFR3-TACC3 fusion proteins as endogenous drivers of resistance in o

57 The fusion proteins as well as the facilitating cellular lip

58 have minimal impact on the properties of the fusion protein, as they have no propensity to form order

59 Here, we present the structure of the G fusion protein at intermediate pH for two vesiculoviruse

60 of TALE constructs with DNMT3A-CD or TET1-CD fusion proteins at the targeted site of the Ascl1 promot

61 we exploited co-expression of an artificial fusion protein, based on the sequence of a DnaJ protein,

62 As therapeutic recombinant fusion proteins become more widely applicable for the tr

63 Here, we developed a fusion protein by linking CD8alpha and MyD88 (CD8alpha:M

64 Such fusion proteins can enhance the efficacy of allergen-spe

65 Recombinant DCN fusion protein CAR-DCN was engineered with an extended C

66 5;17) translocation generates a PML-RARalpha fusion protein causative for acute promyelocytic leukemi

67 Expression of oncogenic SS18-SSX fusion proteins caused profound ATRi sensitivity and a r

68 normalities in AML, leads to expression of a fusion protein CBFbeta-SMMHC (CM) known to disrupt myelo

69 support further evaluations of pretargeting fusion protein cocktails as a strategy to enhance nanopa

70 Human DCs treated with CTLA4-Ig, a fusion protein composed of the Fc region of IgG1 and the

71 we describe the development of a recombinant fusion protein comprised of a cowpox virus encoded NKG2D

72 we describe the development of a recombinant fusion protein comprised of SDF1 and an elastin-like pep

73 To this end, we generated a fusion protein comprising a monovalent human FcgammaRIII

74 ineered latent membrane protein 1 (LMP)/CD40 fusion protein conferring constitutive CD40 signaling un

75 vivo by Mef2c-Dam adenine methyltransferase fusion protein confirmed the link between cognitive enha

76 ion of CLCF1 and BTLA expression, and ZNF384 fusion proteins consistently showed higher activity to p

77 s Metnase (also known as SETMAR), a chimeric fusion protein consisting of a su(var)3-9, enhancer-of-z

78 l drug to treat chronic pain, we developed a fusion protein consisting of two prototypic regulatory c

79 orementioned effector mechanisms, a panel of fusion proteins consisting of a CD20 or CD52 epitope att

80 ntional influenza vaccines, a new 4M2e-tFliC fusion protein construct containing M2e sequences from d

81 apture in immunoassays, using a bifunctional fusion protein construct which incorporates a substrate-

82 on protein methodologies and use appropriate fusion protein constructs to demonstrate mitochondrial a

83 e changes in the DNA of living cells using a fusion protein containing a catalytically defective Stre

84 Treatment with a fusion protein containing E2 domain inhibited cell adhes

85 Mice were immunized with a recombinant fusion protein containing Pca1.

86 Cdkn2a) promoter driving the expression of a fusion protein containing synthetic Renilla luciferase a

87 C3P3, a fusion protein containing T7 RNA polymerase and NP868R,

88 of immune modulation by a flagellin:allergen fusion protein containing the Toll-like receptor 5 ligan

89 r basis of this inhibition, we generated GST fusion proteins containing PEX9 or truncated forms corre

90 that immune responses to the more conserved fusion protein contribute to protection against heterolo

91 uptake vs. non-biotinylated nanoparticle and fusion protein controls.

92 The development of the fusion protein CTLA-4-Ig as an experimental and subseque

93 s comprise a unique family of viral membrane fusion proteins dedicated to inducing cell-cell fusion.

94 Finally, we present a workflow for fusion protein design and discuss best practices for eng

95 A fusion protein designed in order to combine the fluoresc

96 The DNA plasmid encoded a MultiHIV B clade fusion protein designed to induce cellular immunity.

97 tial order of allergen and adjuvant within a fusion protein determines its immunologic characteristic

98 This study reveals that the leukemogenic CM fusion protein disrupts adult erythropoiesis and creates

99 However, these fusion proteins do not incorporate to full occupancy and

100 y captured by an immobilized SpyCatcher-SrtA fusion protein during purification.

101 y are homologous to EFF-1 and viral class II fusion proteins (e.g., Zika virus).

102 crotubule-associated protein L chain 3 (LC3) fusion protein effectively enhances and broadens HS CD4(

103 prion-like domain of the oncogenic EWS-FLI1 fusion protein enables phase-separation events, which in

104 To constrain stoichiometry, fusion proteins encoding concatemers of human alpha3, be

105 e small-molecule inhibitors of other class I fusion proteins enhances our understanding of how small

106 lation with an EphB2 extracellular domain-Fc fusion protein (EphB2-Fc) induces RhoA activation and en

107 We name this superfamily Fusexins: fusion proteins essential for sexual reproduction and ex

108 By analyzing the localization of a Cdh2-EGFP fusion protein expressed under the control of the zebraf

109 a combination of CDV attachment protein- and fusion protein-expressing recombinant viruses were prote

110 5-vectored vaccine expressing the native RSV fusion protein (F) has previously been shown to confer r

111 The RSV fusion protein (F) is essential for virus entry because

112 The RSV fusion protein (F) is highly conserved and is the only v

113 IV5 was engineered to express either the RSV fusion protein (F) or the RSV major attachment glycoprot

114 ectored vaccine candidate expressing the RSV fusion protein (F) that was immunogenic and protective i

115 phosphoprotein (P), matrix protein (M), and fusion protein (F) were required for formation of filame

116 dosomal protease for activation of the viral fusion protein (F).

117 Paramyxovirus viral fusion proteins (F) insert into the target cell membrane

118 Although the MLL-CHD fusion protein failed to immortalize HSPCs in myeloid co

119 e combines several functions within a single fusion protein for mediating targeted cell penetration a

120 ith Gaussia princeps luciferase TNFSF ligand fusion proteins for cell-bound TNFRSF members on intact

121 fusion and is remarkably similar to class II fusion proteins found in viruses such as dengue and Zika

122 In this study, we engineered a bispecific fusion protein (FP) that evades the limitations imposed

123 nctional effects of ETO2-GLIS2, an oncogenic fusion protein frequently encountered in AMKL, and eluci

124 RhoGC is a fusion protein from the aquatic fungus Blastocladiella e

125 pull-down ligands to selectively enrich GFP fusion proteins from cell extracts, and as affinity colu

126 , at least in part, by inhibition of EWS/ETS fusion protein function that results in derepression of

127 h affinity of the combinatorial domain 11 Fc fusion proteins functioned as ligand-soluble antagonists

128 BAR-domain proteins such as the fusion proteins Fus2p and Rvs161p are known to recognize

129 ion of mitochondrial outer or inner membrane fusion proteins (Fzo1p or Mgm1p) leads to decreased accu

130 cluster in the cytoplasmic domain of the VZV fusion protein, gB, in the formation of VZV induced mult

131 We also show that the fusion protein generated from the originally described D

132 gL ancillary complexes and the homo-trimeric fusion protein glycoprotein B (gB).

133 Unlike other class I viral fusion proteins, GPC retains its stable signal peptide (

134 The IL4-10 fusion protein has potential as a treatment for persiste

135 The Vmh2-GFP fusion protein has proven to be a smart and effective to

136 The fusion proteins have similar in vitro biological activit

137 We have generated a hexameric-Fc fusion protein (hexameric-Fc) and tested the consequence

138 cells, we engineered CD200R immunomodulatory fusion proteins (IFPs) with the cytoplasmic tail replace

139 Furthermore, expression of a Nup98 fusion protein implicated in aggressive AML causes mislo

140 refusion and postfusion conformations of the fusion protein.IMPORTANCE Due to lapses in vaccination w

141 inal fusions, this virus expresses more VP26 fusion protein in infected cells and incorporates more V

142 el of IFNgamma induction and an IFNgamma-GFP fusion protein in large, vascularized tumours growing in

143 on catabolites formed by proteolysis of the fusion protein in rabbit following intravenous administr

144 n fluorescent protein [eGFP]) or an NSs-eGFP fusion protein in the NSs locus.

145 suppressor in B-ALL, while the role of PAX5 fusion proteins in B-ALL development is largely unknown.

146 FRET efficiency and photostability of tandem fusion proteins in mammalian cells.

147 Mice were immunized with the fusion proteins in the absence and presence of aluminum

148 islocalize transmembrane and cytoplasmic GFP fusion proteins in the Drosophila wing disc epithelium a

149 ple, in the encapsulation of enzymes and for fusion proteins in tissue regeneration.

150 pretargeting strategy exploiting recombinant fusion proteins in which a soluble form of TRAIL, FasL o

151 ift46-1 allele, causing the expression of a fusion protein including the IFT46 C-terminal 240 amino

152 the characteristics of FPs of class I viral fusion proteins, including high Ala/Gly content, interme

153 Chimeric antigen receptors (CARs) are fusion proteins incorporating antigen-recognition domain

154 Fusion proteins incorporating the Toll-like receptor 5 l

155 Localization studies, utilizing GFP-OsGRXS17 fusion proteins, indicated that OsGRXS17 resides in both

156 is required for specific suppression of MLL fusion protein-induced leukemogenesis both in vitro and

157 in infected cells and incorporates more VP26 fusion protein into virus particles, and individual viru

158 ts, these structural abnormalities result in fusion proteins involving transcription factors importan

159 rs show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and

160 The green fluorescent protein (GFP)-SEC3a fusion protein is functional and accumulates at or proxi

161 As the largest known class I fusion protein, its size and extensive glycosylation hav

162 d Dusp1 suppressed tumor growth in a BCR-ABL fusion protein kinase-induced mouse model of chronic mye

163 h differential genomic target binding of the fusion proteins leading to specific gene expression patt

164 monstrate efficacy and safety of recombinant fusion protein linking coagulation factor IX (FIX) with

165 We used IKs fusion proteins linking KCNE1 to one (EQ), two (EQQ) or

166 Finally, BRX-OPS as well as OPS-BRX fusion proteins localize to the rootward end of developi

167 bound chitin and an SnTox1-green fluorescent fusion protein localized to the mycelial cell wall.

168 A SigG-GFP translational fusion protein localized to the periphery of vegetative

169 ing domain for interaction with the membrane fusion protein MacA.

170 single-protein convenience of integrase-RDF fusion proteins make them potentially very advantageous

171 tagonists even when formatted as bivalent Fc-fusion proteins, making this an attractive therapeutic f

172 ji and Jurkat tumors, pretargeting with both fusion proteins markedly increased nanoparticle targetin

173 Both fusion proteins matured monocyte-derived dendritic cells

174 Thus, FGFR3-TACC3 fusion proteins may represent a novel mechanism of acqui

175 tible with subcellular localization SNAP-tag fusion protein methodologies and use appropriate fusion

176 trafficking adaptors, and the mitochondrial fusion proteins (mitofusins).

177 e with multiple partner genes creating novel fusion proteins (MLL-FPs) that cause aggressive acute le

178 ter membrane component MtrE and the membrane fusion protein MtrC, obtained by a combination of planar

179 l melanoma-specific transcripts that include fusion proteins, novel exons and non-coding RNAs, one-th

180 carry the t(2;5; p23;q35) that produces the fusion protein NPM-ALK (nucleophosmin-anaplastic lymphom

181 ramyxoviruses, activation of the henipavirus fusion protein occurs in recycling endosomal compartment

182 potential adenoviral vaccines that express a fusion protein of HPV-16 E6 and E7 (Ad.E6E7) alone or fu

183 ns, we created a novel chimeric IL2-IL2Rbeta fusion protein of IL2 and its receptor IL2Rbeta joined v

184 conjugated to a genetically encoded HaloTag fusion protein of known cellular localization.

185 pe 35 adenovirus containing DNA expressing a fusion protein of Mtb antigens 85A, 85B and TB10.4.

186 o overcome these limitations, we developed a fusion protein of the anti-inflammatory cytokines interl

187 Full-length NCX1 (FL-NCX1) and a YFP fusion protein of the NCX1 large intracellular loop (YFP

188 We previously designed a fusion protein of TM [single-chain variable fragment ant

189 We generated flies expressing fusion proteins of alpha-tubulin and rsEGFP2 highlightin

190 Viral membrane fusion proteins of class I are trimers in which the prot

191 Recombinant fusion proteins of flagellin and antigens have been demo

192 We sought to characterize different fusion proteins of flagellin and the major birch pollen

193 we tested whether immunoregulatory cytokine fusion proteins of IL-10/Fc, TGF-beta/Fc, or IL-2/Fc wou

194 Within the class I viral fusion proteins of many enveloped viruses, the FP is the

195 cells (hPSCs) to express various N-terminal fusion proteins of the telomerase reverse transcriptase

196 ysts through constructing and characterizing fusion proteins of TxtE with the reductase domain of CYP

197 re, we examine the role of the mitochondrial fusion protein optic atrophy 1 (OPA1) in differentiated

198 ate that expression of either the endogenous fusion protein or a chimeric cDNA leads to the formation

199 dependent on the availability of fluorescent fusion proteins or highly specific and sensitive antibod

200 at were previously not observed using Httex1 fusion proteins or Httex1 proteins produced by in situ c

201 al or intracerebroventricular routes or with fusion proteins, or gene therapy) or applicable to more

202 ed in this manuscript shows that this IL4-10 fusion protein overcomes some major therapeutic limitati

203 2 has been further elucidated by a generated fusion protein PeCBM32-eGFP that binds to the chitosan e

204 abilisation, and also how a leukaemogenic TF fusion protein perturbs key HSPC regulators.

205 resulting in expression of a PAX8-PPARgamma fusion protein, PPFP.

206 D-L1 antibodies, OX40 ligand, or GITR ligand fusion proteins, produced synergistic antitumor response

207 tions, but the molecular principles by which fusion protein products affect interaction networks and

208 echanistic insight into which Nup98 leukemic fusion proteins promote AML.

209 ant cell lines demonstrated that FGFR3-TACC3 fusion proteins promote resistance by preferentially sub

210 Furthermore, although FGFR3-TACC3 fusion proteins promote resistance of additional EGFR-de

211 quent analyses revealed that the ZNF767-BRAF fusion protein promotes RAF dimerization and activation

212 catabolite information for this recombinant fusion protein, providing valuable insight into the inte

213 s of the TNFSF ligand G. princeps luciferase-fusion proteins ranged between 0.01 and 19 nm and offer

214 The fusion protein recapitulates the functional and structur

215 integrase-RDF linker peptide did not affect fusion protein recombination activity.

216 The fusion protein reduced colonization by Staphylococcus au

217 Furthermore, CHIR fusion proteins reduced AIV-induced in vitro activation

218 ession constructs for crystallization of MBP fusion proteins remains a challenge.

219 BioID2 enables more-selective targeting of fusion proteins, requires less biotin supplementation, a

220 The fusion proteins retain the antigen binding activity of t

221 rabidopsis lines stably transformed with GFP fusion proteins revealed that DHAR1 and DHAR2 are cytoso

222 Mutagenesis of a SHIP-enhanced GFP fusion protein reveals that the SHIP-Src homology 2 doma

223 pharmacokinetics of recombinant factor IX Fc fusion protein (rFIXFc) in previously treated paediatric

224 the control of tamoxifen-activated Cre-ER(T) fusion protein, robustly increased expression of proinfl

225 Escherichia coli We produced a rPfs25-PfMSP8 fusion protein [rPfs25/8(CDeltaS)] as well as unfused, m

226 ved by recrystallizing a recombinant S-layer fusion protein (rSbpA/ZZ) on the surface of the sensors.

227 In a similar pretargeting setting, fusion protein scFvFITC:sCD40L promoted tumour-directed

228 Fusion proteins scFvFITC:sTRAIL and scFvFITC:sFasL induc

229 that this spatiotemporal association of the fusion proteins selectively alters the methylation state

230 We investigated two such fusion proteins, SET-Nup214 and SQSTM1 (sequestosome)-Nu

231 Bet v 1-flagellin fusion proteins show enhanced immunogenicity, reduced al

232 Finally, this fusion protein showed potent in vivo efficacy in the del

233 Compared with Bet v 1, the fusion proteins showed stronger T cell-stimulatory and r

234 xtends this description to "class III" viral fusion proteins, showing that reversibility of the low-p

235 model, treatment with an antagonist Ox40:Fc fusion protein significantly delayed the onset of severe

236 ing neutrophil degranulation with TAT-SNAP23 fusion protein significantly reduced the chemotactic and

237 oadly neutralizing, defucosylated hexavalent fusion protein specific for both the CD4 and coreceptor

238 oadly neutralizing, defucosylated hexavalent fusion protein specific for both the CD4 and coreceptor

239 a commercially available TGFbeta receptor-Fc fusion protein (sTbetaRII) in the presence of TGFbeta.

240 ow it to be overcome upon demand by specific fusion proteins [such as soluble N-ethylmaleimide-sensit

241 elationship efforts led to generation of the fusion protein Syn-Vm24-CDR3L, which demonstrated excell

242 Using a glucocorticoid receptor (GR)-based fusion protein system to conditionally localize GR-UVR8

243 Fusion proteins targeting CD20 or tumor-associated glyco

244 ependent expression of a GFP-tagged ferritin fusion protein tethered to the cation-conducting transie

245 Luspatercept (ACE-536) is a novel fusion protein that blocks transforming growth factor be

246 r which we developed an anti-CD38-bispecific fusion protein that eliminates endogenous biotin interfe

247 i-Fcgamma receptor III (FcgammaRIII)-albumin fusion protein that inhibits the development of thromboc

248 ansplant patients is belatacept (Nulojix), a fusion protein that interferes with cytotoxic T lymphocy

249 (CAR) are clinically translatable synthetic fusion proteins that can redirect the specificity of T c

250 from Pseudomonas exotoxin are antibody-toxin fusion proteins that inhibit protein synthesis of mammal

251 nslocations that result in the expression of fusion proteins that typically involve genes encoding ty

252 es of the Fas death receptor, the HIV-1 gp41 fusion protein, the influenza proton channel, and the MC

253 nsition and architectural differences in the fusion proteins themselves do not change the basic mecha

254 F-alpha in vivo with the soluble recombinant fusion protein TNFR:Fc slowed disease progression in Umo

255 We used a soluble IN fusion protein to facilitate structural studies, through

256 Targeting of the dCas9-Tet1 or -Dnmt3a fusion protein to methylated or unmethylated promoter se

257 sphoribulokinase-neomycin phosphotransferase fusion protein to produce a high-fidelity, high-throughp

258 ant (Kd) for the binding of free SDF1 or the fusion protein to the CXCR4 receptor.

259 the BAF complex is recruited by the EWS-FLI1 fusion protein to tumor-specific enhancers and contribut

260 or genome targeting with Fkbp/Frb dimerizing fusion proteins to allow chemical-induced proximity of a

261 ughout muNS, and the capacity of the TC-muNS fusion proteins to form virus factory-like (VFL) structu

262 gonistic monoclonal antibodies and agonistic fusion proteins to inhibit or potentiate these molecules

263 , nonlytic IL-2/Fc, TGF-beta/Fc, or IL-10/Fc fusion proteins to promote chimerism to induce tolerance

264 lity of Rap1-heterologous DNA-binding domain fusion proteins to serve as chimeric transcriptional act

265 fficient to direct green fluorescent protein fusion proteins to specific membranes in human cells, bu

266 ment) or nonlytic IL-2/Fc (10-day treatment) fusion proteins to the conditioning resulted in engraftm

267 s, including endogenous neuropeptides, viral fusion proteins, topogenic peptides, and amyloids.

268 BMC engraftment is enhanced with TGF-beta/Fc fusion protein treatment.

269 ated by a conformational change in the viral fusion protein, triggered by receptor binding, an enviro

270 While gB represents the fusion protein, two glycoprotein complexes control the t

271 d by low-pH preexposure, and gB, a class III fusion protein, undergoes reversible conformational chan

272 on and stoichiometry of a functional GFP-Mrr fusion protein using in vivo fluorescence fluctuation mi

273 nt form as a green fluorescent protein (GFP) fusion protein (VP1L138P-GFP) (i) in wild-type SA11-infe

274 ontaining LUJV GP as its sole attachment and fusion protein (VSV-LUJV), we demonstrate that infection

275 e vector BNSP333, and the RABV G-MERS-CoV S1 fusion protein was efficiently expressed and incorporate

276 Purified fusion protein was encapsulate into MNPs with a biocompa

277 in which the tamoxifen-inducible p53ER(TAM) fusion protein was expressed from a knock-in allele (Th-

278 AtHEMN1-green fluorescent protein fusion protein was found targeted to mitochondria.

279 Moreover, a GPD2-mCherry fusion protein was found to localize to the chloroplast,

280 The IL4-10 fusion protein was more effective than the individual cy

281 Moreover, an enhanced GFP-SATB1 fusion protein was rapidly recruited to laser microirrad

282 e specific cutting site of the thrombin, the fusion protein was used as the active biological element

283 This fusion protein was used to deliver fluorescently labeled

284 The T cell-stimulatory capacity of the fusion proteins was assessed with naive and Bet v 1-spec

285 in vivo localization of fluorescently tagged fusion proteins, we show that CSLD5 preferentially accum

286 nhanced yellow fluorescent protein when both fusion proteins were coexpressed.

287 Both OsCCR4a and OsCCR4b fluorescent fusion proteins were localized in the rice cytoplasm and

288 These rcSso7d-CBD fusion proteins were solubly expressed and purified from

289 Here, we present a fusion protein where thrombin and the EGF456 domain of t

290 l translocation that results in an oncogenic fusion protein, whereas pleomorphic liposarcoma is a kar

291 d on an engineered, allosterically activated fusion protein, which contains the ligand binding domain

292 trans-signaling, or soluble glycoprotein 130 fusion protein, which selectively blocks trans-signaling

293 mixed-lineage leukemia gene (MLL) create MLL-fusion proteins, which could drive both acute lymphoblas

294 led that resistant cells express FGFR3-TACC3 fusion proteins, which were validated as drivers of the

295 s a monomeric red fluorescent protein (mRFP) fusion protein with a signal peptide to secrete it from

296 In conclusion, we developed a novel fusion protein with improved efficacy to treat pain, com

297 K9 with a high affinity and produced them as fusion proteins with a mouse Fc.

298 The interaction of the fusion proteins with CRM1 is RanGTP-dependent, as shown

299 ltransferase MLL1 (KMT2A) generate oncogenic fusion proteins with deregulated transcriptional potenti

300 structurally categorized as a class I viral fusion protein, within the same group as influenza virus